SCHEMBL12417819

SCHEMBL12417819

[C-]#[N+]C1(NC(=O)[C@H](CC(F)(F)CC2CC2)N[C@@H](c2ccc(F)cc2)C(F)(F)F)CC1

nearest known ligand 0.49

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
CTSS P25774 15/20 0.49
CTSL P07711 13/20 0.49
CTSB P07858 11/20 0.49
CTSK P43235 9/20 0.49

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12417822 0.87 CTSL (0.50) CTSSCTSLCTSBCTSK
SCHEMBL12417835 0.86 CTSS (0.48) CTSSCTSLCTSBCTSK
SCHEMBL12417826 0.85 CTSL (0.48) CTSSCTSLCTSBCTSK
SCHEMBL12417829 0.84 CTSL (0.47) CTSSCTSLCTSBCTSK
SCHEMBL12417840 0.84 CTSS (0.53) CTSSCTSLCTSBCTSK
SCHEMBL1200545 0.83 CTSS (0.72) CTSSCTSLCTSBCTSK
SCHEMBL1200546 0.83 CTSS (0.72) CTSSCTSLCTSBCTSK
SCHEMBL12417845 0.81 CTSS (0.47) CTSSCTSLCTSBCTSK
SCHEMBL13584817 0.80 CTSS (0.46) CTSSCTSLCTSBCTSK
SCHEMBL12876985 0.80 CTSS (0.46) CTSSCTSLCTSBCTSK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-08-07 US disclosed
US-8748649-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2014-06-10 US disclosed
US-20140018421-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2014-01-16 US disclosed
US-8367732-B2 Di-fluoro containing compounds as cysteine protease inhibitors VIROBAY, INC. (US) 2013-02-05 US disclosed
US-20120329837-A1 CATHEPSIN INHIBITORS FOR TREATING MICROGLIA-MEDIATED NEURON LOSS IN THE CENTRAL NERVOUS SYSTEM VIROBAY, INC. (US) 2012-12-27 US disclosed
US-20110172310-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2011-07-14 US disclosed
US-7893112-B2 N-(1-cyanocyclopropyl)-4,4-difluoro-2(S)-[2,2,2-trifluoro-1(S)-(4-fluorophenyl)ethylamino)octamide; rheumatoid arthritis, multiple sclerosis, myasthenia gravis, psoriasis, pemphigus vulgaris, Graves' disease, myasthenia gravis, lupus, asthma, pain, atherosclerosis; cathepsins B, K, L, F, and S inhibitors VIROBAY, INC. (US) 2011-02-22 US disclosed
US-20080293819-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS VIROBAY, INC. (US) 2008-11-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080293819-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS CTSS 3/4885CTSL 10/4885CTSB 4/4885
US-20120329837-A1 CATHEPSIN INHIBITORS FOR TREATING MICROGLIA-MEDIATED NEURON LOSS IN THE CENTRAL NERVOUS SYSTEM CTSS, CTSB, CTSG CTSS 1/4885CTSL 12/4885CTSB 2/4885
US-20140221478-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS CTSS 3/4885CTSL 10/4885CTSB 4/4885
US-20110172310-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS CTSS 3/4885CTSL 10/4885CTSB 4/4885
US-20140018421-A1 DI-FLUORO CONTAINING COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS CTSF, CTSZ, CTSS CTSS 3/4885CTSL 10/4885CTSB 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.